Lubiprostone: chronic constipation and irritable bowel syndrome with constipation

Bibliography

• Higgins PDR, Johanson JF. Epidemiology of chronic constipation in North America: a systematic review. Am J Gastroenterol 2004;99:750-9
   PubMed Web of Science ®Google Scholar
• Lacy BE, Cole MS. Constipation in the older adult. Clin Geriatr 2004;12:44-54
   Google Scholar
• Irvine EJ, Ferrazzi S, Pare P, et al. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol 2002;97:1986-93
   PubMed Web of Science ®Google Scholar
• Dennison C, Prasad M, Lloyd A, et al. The health-related quality of life and economic burden of constipation. Pharmacoeconomics 2005;23:461-7
   PubMed Web of Science ®Google Scholar
• Talley NJ, Weaver AL, Zinsmeister AR, et al. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992;136:165-77
   PubMed Web of Science ®Google Scholar
• Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991;101:927-34
   PubMed Web of Science ®Google Scholar
• Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993;38:1569-80
   PubMed Web of Science ®Google Scholar
• Saito YA, Locke GR, Talley NJ, et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000;95:2816-24
   PubMed Web of Science ®Google Scholar
• Luscombe FA. Health-related quality of life and associated psychosocial factors in irritable bowel syndrome: a review. Qual Life Res 2000;9:161-76
   PubMed Web of Science ®Google Scholar
• Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestives diseases in the United States. Gastroenterology 2002;122:1500-11
   PubMed Web of Science ®Google Scholar
• Levy RL, Von Korff M, Whitehead WE, et al. Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol 2001;96:3122-9
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
   PubMed Web of Science ®Google Scholar
• Brandt LJ, Prather CM, Quigley EMM, et al. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol 2005;100:S5-22
   PubMedGoogle Scholar
• Young RJ, Beerman LE, Vanderhoof JA. Increasing oral fluids in chronic constipation in children. Gastroenterol Nurs 1998;21:156-61
   PubMedGoogle Scholar
• Muller-Lissner SA, Kamm MA, Scarpignato C, Wald A. Myths and misconceptions about chronic constipation. Am J Gastroenterol 2005;100:232-42
   PubMed Web of Science ®Google Scholar
• Cash BD, Lacy BE. Systematic review: FDA-approved prescription medications for adults with constipation. Gastroenterol Hepatol 2006;2:736-49
   Google Scholar
• Chen TY. Structure and function of ClC channels. Annu Rev Physiol 2005;67:809-39
   PubMed Web of Science ®Google Scholar
• Suzuki M, Morita T, Iwamoto T. Diversity of Cl channels. Cell Mol Life Sci 2006;63:12-24
   PubMed Web of Science ®Google Scholar
• Mindell JA, Maduke M. ClC chloride channels. Genome Biol 2001;2:3003.1-3003.6
   Web of Science ®Google Scholar
• Lipecka J, Bali M, Thomas A, et al. Distribution of ClC-2 chloride channel in rat and human epithelial tissues. Am J Physiol Cell Physiol 2002;282:C805-16
   PubMed Web of Science ®Google Scholar
• AMITIZA® (lubiprostone) [package insert]. Bethesda, MD: Sucampo Pharmaceuticals, Inc; 2006
   Google Scholar
• Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004;287:C1173-83
   PubMed Web of Science ®Google Scholar
• Bao HF, Liu L, Self J, et al. A synthetic prostone activates apical chloride channels in A6 epithelial cells. Am J Physiol Gastrointest Liver Physiol 2008;295:234-51
   PubMed Web of Science ®Google Scholar
• Ueno R, Osama H, Habe T, et al. Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels. Gastroenterol 2004;126:A298
   Web of Science ®Google Scholar
• Perentesis GP, Crawford DF, Engelke KJ, et al. Effects of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle. Am J Gastroenterol 2005;100:S330
   Google Scholar
• Cuppoletti J, Malinowska DH, Chakrabarti J, Ueno R. Effects of lubiprostone on human uterine smooth muscle cells. Prostaglandins Other Lipid Med 2008;86:56-60
   PubMed Web of Science ®Google Scholar
• Bassil AK, Borman RA, Jarvie EM, et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 2008;154:126-35
   PubMed Web of Science ®Google Scholar
• Grider JR, Jin JG. Distinct populations of sensory neurons mediate the peristaltic reflex elicited by muscle stretch and mucosal stimulation. J Neurosci 1994;14:2854-60
   PubMed Web of Science ®Google Scholar
• Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006;290:G942-7
   PubMed Web of Science ®Google Scholar
• Crawford DF, Perentesis GP, Engelke KJ, Ueno R. Effects of lubiprostone, a novel GI chloride channel activator, on reproductive and developmental toxicity endpoints in rats. Am J Gastroenterol 2005;100:S331
   Web of Science ®Google Scholar
• Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007;25:1351-61
   PubMed Web of Science ®Google Scholar
• Johanson JF, Morton D, Geenan J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2007;103:170-7
   PubMedGoogle Scholar
• Johanson JF, Gargano MA, Holland PC, et al. Initial and sustained effects of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: data from a 4-week Phase III study. Am J Gastroenterol 2005;100:S324-5
   Google Scholar
• Johanson JF, Gargano MA, Holland PC, et al. Phase III study of lubiprostone, a chloride channel-2 (ClC-2) activator for the treatment of constipation: safety and primacy efficacy. Am J Gastroenterol 2005;100:S328-9
   Web of Science ®Google Scholar
• Johanson JF, Gargano MA, Holland PC, et al. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterol 2004;126:A100
   Web of Science ®Google Scholar
• Johanson JF, Panas R, Holland PC, Ueno R. Long-term efficacy of lubiprostone for the treatment of chronic constipation. Gastroenterol 2006;130:A317
   Web of Science ®Google Scholar
• Ueno R, Joswick TR, Wahle A, et al. Efficacy and safety of lubiprostone for the treatment of chronic constipation in male vs.female subjects. Gastroenterol 2006;130:A322
   Web of Science ®Google Scholar
• Johanson JF, Drossman DA, Panas R, et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008;27:685-96
   PubMed Web of Science ®Google Scholar
• Drossman DA, Chey WD, Panas R, et al. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two, twelve-week, randomized, placebo-controlled, double blind trials. Gastroenterol 2007;132:2586-7
   Web of Science ®Google Scholar
• Chey WD, Drossman DA, Scott C, et al. Lubiprostone is effective and well tolerated through 48 weeks of treatment in adults with irritable bowel syndrome and constipation. Gastroenterology 2008;134(Suppl 1):A215
   PubMedGoogle Scholar
• Ueno R. Multiple, escalating, oral-dose study to assess the safety, tolerance, and pharmacodynamic profile of lubiprostone in normal healthy volunteers. Neurogastroenterol Motil 2005;17:626
   Google Scholar
• Rivera E, Wahle A, Joswick TR, Ueno R. Lubiprostone, a novel type-2 chloride channel (Clc-2) activator, does not affect serum electrolyte balance in elderly and non-elderly patients with chronic idiopathic constipation. Gastroenterol 2007;132:A191-2
   Web of Science ®Google Scholar
• Sprenger C, Copa A, Morganroth J, et al. Effect of lubiprostone, a unique agent for the treatment of chronic idiopathic constipation, on clinical electrocardiogram results. Gastroenterol 2007;132:A325
   Web of Science ®Google Scholar
• Ueno R, Hiroyoshi O, Engelke KJ. Effect of lubiprostone on morphine-induced constipation and analgesia. Gastroenterol 2006;130:A373-4
   PubMed Web of Science ®Google Scholar
• Moeser AJ, Nighot PK, Engelke KJ, et al. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 2007;292:G647-56
   PubMed Web of Science ®Google Scholar